Salute e Benessere

Cepheid and Oxford Nanopore Technologies Partner to Advance Automated…

The two companies have completed a successful proof-of-concept study which demonstrated the feasibility of using Cepheid's cartridge-based GeneXpert system for sample and library preparation in a workflow with Oxford Nanopore's sequencing platform. The positive results from the proof-of-concept have paved the way for the strategic collaboration to develop and launch a joint Research Use Only1 (RUO) workflow that will enable customers to leverage rapid, information-rich sequencing in-house for…
PR Newswire
09/04/2025

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23…

ORION CORPORATIONPRESS RELEASE9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday, 23 April 2025 at approximately 12.00 noon EEST. The release and related presentation material will be available on the company's website atwww.orionpharma.com/investorsafter publishing. Webcast and conference call A webcast and a conference...
Nasdaq GlobeNewswire
09/04/2025

EQT to sell Karo Healthcare, a Leading Pan-European Consumer health Platform, to…

Under EQT's ownership since 2019, Karo has undergone a significant strategic repositioning, shifting from a specialty pharmaceutical company focused on the Nordics into becoming a pan-European pure-play consumer healthcare platform. During this time, with M&A having been a cornerstone of Karo's growth strategy, Karo completed eight acquisitions from industry players which have enriched Karo's portfolio, strengthened its presence in key markets, and accelerated its entry into new geographies…
PR Newswire
09/04/2025

Zentiva presents its Sustainability Report 2024

Ines Windisch, Head of Communications, Corporate Affairs & Sustainability, said: "The achievements were only possible thanks to the engagement of our workforce and our partners. Understanding the impact we have as individuals, as a team, and as a company helps us to take the right actions, focusing on caring for people, partners, and our planet." The company reports a reduction of more than 20% in GHG emissions in Scope 1 over the last three years. All European...
PR Newswire
09/04/2025

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate…

The VISTA* study is a phase I/IIa double-blind, randomised, placebo-controlled trial to assess the safety, tolerability and anti-tumour activity of ITOP1 in reducing OAC recurrence rates. 60 patients will receive ITOP1 in a prime/boost regimen, in combination with the best standard of care, i.e., a priming dose following neoadjuvant and a boost dose before adjuvant FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy. Infinitopes' VISTA trial will be one of the first in the…
PR Newswire
09/04/2025

Oxygen-starved cancer cells develop similar survival strategies as the Sherpa…

"With this study, we aimed to achieve deeper insights into how tumors can survive, grow, and even metastasize under low oxygen conditions, known as hypoxia. Our findings reveal a broad convergence in genetic adaptation in tumors that continue to develop and grow under hypoxia, and in high-altitude populations who thrive in such a challenging environment," said Rodrigo Toledo, corresponding author of this present article. "With this study, we aimed to achieve deeper insights into…
PR Newswire
09/04/2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on…

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the Company...
Nasdaq GlobeNewswire
09/04/2025

The effect of aprocitentan for reducing blood pressure and proteinuria in Black…

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertensionAllschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of " Aprocitentan for Blood Pressure Reduction in Black Patients ” in the April edition ofHypertension1. The publication reports preplanned analyses of the efficacy, tolerability and safety of...
Nasdaq GlobeNewswire
09/04/2025

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of…

Saint Herblain (France) and Schlieren (Zurich) ,April 9, 2025 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, andLimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate vaccine candidate...
Nasdaq GlobeNewswire
09/04/2025

US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS…

Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced on March 17, 2025 ), has now approved the updated label for TRYVIO™ (aprocitentan). TRYVIO is Idorsia's dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood...
Nasdaq GlobeNewswire
09/04/2025

TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant…

Servier's TIBSOVO (ivosidenib) Overview Servier's TIBSOVO (ivosidenib) Overview TIBSOVO (ivosidenib) is a small molecule developed by Servier, acts as an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test. Currently, TIBSOVO is approved for the treatment of newly diagnosed acute myeloid leukemia (AML), relapsed or refractory AML, relapsed or refractory myelodysplastic syndromes...
PR Newswire
08/04/2025

Medical Rubber Stoppers Market Size Worth USD 1619 Million by 2030 - CAGR 4.8% |…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-31H8852/Global_Medical_Rubber_Stoppers_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-31H8852/Global_Medical_Rubber_Stoppers_Market Major Factors Driving the Growth of Medical Rubber Stoppers Market: The Medical Rubber Stoppers Market thrives on the convergence of public health imperatives, pharmaceutical innovation, and regulatory compliance. As producers explore...
PR Newswire
08/04/2025

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit…

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated...
Nasdaq GlobeNewswire
08/04/2025

EssilorLuxottica: Disclosure of transactions in own shares

Disclosure of transactions in own shares Paris, France (April 8, 2025 - 6:15 pm)– In accordance with the authorization granted by the Annual Shareholders' Meeting on April 30, 2024, EssilorLuxottica declares that from April 3, 2025, to April 7, 2025, inclusive, the following share buybacks were carried out: Name of the issuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily...
Nasdaq GlobeNewswire
08/04/2025

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES Ghent, Belgium, 8 April 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that, in the context of a contribution in kind of a EUR 400,000.00 commitment fee outstanding under the share subscription facility agreement entered into on 17 March 2025 between…
Nasdaq GlobeNewswire
08/04/2025

Ipsen publishes its 2024 Universal Registration Document

Ipsen publishes its2024 Universal Registration DocumentPARIS, FRANCE, 8 April 2025- Ipsen (Euronext: IPN; ADR: IPSEY) announced today the filing of its 2024 Universal Registration Document with the FrenchAutorité des Marchés Financiers(AMF) on 7 April 2025 and registered under the number D.25-0232.The document is available onipsen.comandamf-france.org. Copies will also be available at Ipsen's headquarters – 70 rue Balard, 75015 Paris, France.The...
Nasdaq GlobeNewswire
08/04/2025

Kemin Industries Mourns the Loss of Co-Founder R.W. Nelson

"We deeply mourn the passing of R.W. – our family patriarch and one of the visionaries behind Kemin. He was beloved by our family, countless customers around the world, and thousands of Kemin employees whose lives he touched for more than six decades," said Dr. Chris Nelson, President and CEO of Kemin Industries and the eldest son of R.W. "He was tirelessly committed to our family, his faith, the community, and was Kemin's most dedicated marketer and sales champion, coming to the…
PR Newswire
08/04/2025

Smile in Strides: Goody's® Pain Relief Encourages Runners to Harness the Power…

Goody's® published "The Science of Smiling & Benefits to Pain Relief," a white paper on how the physical act of smiling can have a positive impact on pain relief in athletes to demonstrate that smiling is scientifically proven to reduce pain. The white paper reviews a body of research and scientific literature spanning more than 20 years that indicates the act of smiling might offer an unexpected boost during moments of physical pain and exhaustion. The connection is both…
PR Newswire
08/04/2025

Cosmos Health Launches Sky Premium Life in Albania through Partnership with…

Cosmos Health Inc. ("Cosmos Health" or the “Company'')(NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the launch of its Sky Premium Life food supplements brand in Albania, in partnership with Pharma Cell , a leading consumer health and medical...
Nasdaq GlobeNewswire
08/04/2025

US Digital Pathology Market worth US$2.01 billion by 2029 with 13.1% CAGR |…

Browse in-depth TOC on "US Digital Pathology Market" Browse in-depth TOC on "US Digital Pathology Market" 248 - Tables47 - Figures By Based on Scanners segment,In the US, the digital pathology market is classified based on type into scanners, software, and storage systems. In 2023, the scanners segment accounted for the largest share of the product segment. The high demand for scanners is attributed to continuous technical improvements, such as improved imaging resolution,...
PR Newswire
08/04/2025

Care Fertility and U-Ploid Biotechnologies Announce Research Collaboration to…

"We are thrilled to begin this collaborative research with U-Ploid Biotechnologies," said Prof. Alison Campbell, Chief Scientific Officer of Care Fertility. "Advancing knowledge and treatments to support women facing age-related infertility is a priority for Care Fertility and to think that this research could help prevent the most common cause of infertility is extraordinary." "We are thrilled to begin this collaborative research with U-Ploid Biotechnologies," said…
PR Newswire
08/04/2025

Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop…

This announcement follows the recent release of Phase 1 data from AmacaThera's successful first-in-human study, which evaluated AmacaGel™ in combination with an anesthetic. The study generated valuable human data on both the core platform and its integration with a therapeutic payload. This announcement follows the recent release of Phase 1 data from AmacaThera's successful first-in-human study, which evaluated AmacaGel™ in combination with an anesthetic. The study generated valuable human…
PR Newswire
08/04/2025

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of…

"We are honored to welcome Bill Hoffman as Executive Chairman," said Théophile Mohr-Durdez, CEO and co-founder of Volta Medical. "Bill's experience building, commercializing, and scaling, disruptive medical technologies will be invaluable as we accelerate global access to our AI-driven solutions for cardiac ablation." "We are honored to welcomeBill Hoffmanas Executive Chairman," said Théophile Mohr-Durdez, CEO and co-founder of Volta Medical. "Bill's experience…
PR Newswire
08/04/2025

PEPSICO® EXTENDS ITS PARTNERSHIP AS UEFA WOMEN'S FOOTBALL PARTNER THROUGH 2030

As a long-term UEFA Women's Football partner, PepsiCo holds exclusive rights to both the UEFA Women's Champions League (UWCL) from 2025-2030 and the UEFA Women'sEURO 2029. With the newly introduced format of the UWCL making 2025 a defining year for the sport, PepsiCo will kick off the next cycle of its partnership by delivering a bold lineup of initiatives – spanning grassroots football toEurope'stop leagues – designed to elevate the game and create unforgettable experiences...
PR Newswire
08/04/2025
Altri  Comunicati